Dr. Lamon joined Caris Life Sciences in September 2020 and currently serves as Chief Business Officer, Head of BioPharma Business Development. He is responsible for developing the company’s partnering and business development strategy and translating that strategy into actionable and achievable goals for the broader Caris organization.
Dr. Lamon came to Caris with over 15 years of experience from large pharma and academia. He previously worked for Bristol Myers Squibb (BMS) as Vice President, Development Lead, Genitourinary (GU) Malignancies, Oncology Development. Prior to that, he held several leadership roles in clinical development and business development, including Head, Clinical Collaborations & External Evaluations, Chair of the joint development of immuno-oncology collaboration assets in Japan, South Korea and Taiwan, and leadership of the Search & Evaluation team responsible for the identification and assessment of external clinical stage assets for clinical collaborations, licensing and M&A.
Dr. Lamon received his BA in Biology and French from Lafayette College and earned his PhD in Pharmacology from New York Medical. Prior to joining industry, he was Assistant Dean of Research Development and Assistant Professor, Department of Pathology and Laboratory Medicine at Weill Medical College of Cornell University in New York, and he remains active on the faculty as Assistant Professor (courtesy appointment).